|Description||ACH-806 is a Hepatitis C virus NS3 protein inhibitor. It can inhibit viral RNA replication in HCV replicon cells and is active in genotype 1 HCV-infected patients in a proof-of-concept clinical trial. But Phase-II for Hepatitis C treatment was discontinued.|
|Solubility||Soluble in DMSO|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Current Developer||Originator Achillion Pharmaceuticals|
PSI-6206 (RO2433) is a selective HCV RNA polymerase inhibitor. It is the unphosphorylated parent compound of triphosphate analog PSI-7409, which is a potent inh...
Faldaprevir, also called as BI 201335, is a potent, once-daily (QD), hepatitis C virus (HCV) NS3/4A protease inhibitor with the potential to treat HCV infection...
PSI-7409, the active 5′-triphosphate metabolite of PSI-7851, is a potent inhibitor of the HCV NS5B RNA dependent RNA polymerase.
Artemisinin is a drug used to treat multi-drug resistant strains of falciparum malaria.
PSI-7976 is an inhibitor of HCV RNA replication with EC50 value of 1.07μM. PSI-7851 is a phosphoramidate prodrug of PSI-7411 and has potent anti-hepatitis C vir...
Beclabuvir is a potent, non-nucleotide inhibitor of HCV NS5B which is currently in Phase III clinical trials for the treatment of chronic HCV infection. Beclabu...
Radalbuvir is a Hepatitis C virus NS 5 protein inhibitor for the treatment of hepatitis C virus (HCV) infection developed by Gilead Sciences. In 2014, Gilead co...
Daclatasvir dihydrochloride is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype...
PSI-6130 is a potent and selective inhibitor of HCV NS5B polymerase. It is metabolized to two pharmacologically active species in primary human hepatocytes.
Against JFH1/3a-NS5A, DCV was more potent (EC(50) = 0.52 nM) than GS-5885 (EC(50) = 141 nM). DCV sensitivity was increased against JFH1/3a-NS5A-M28V (EC50 = 0.0...
In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical stu...
GSK-2818713 is a second-generation inhibitor of hepatitis C virus (HCV) NS5A replication. Compared to daclatasvir, a first-generation NS5A replication complex i...
Vedroprevir is a selective hepatitis C virus (HCV) NS3 protease inhibitor. It is a pharmaceutical drug that is used in the treatment of hepatitis C virus in pat...
Alisporivir, also known as DEB-025, a non-immunosuppressive cyclosporine A derivative, is acyclophil ininhibitor molecule with potent anti-hepatitis C virus (HC...
Danoprevir(ITMN-191;R7227; RO5190591;RG7227) is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition...
Elbasvir has been found to restrain viral phosphoprotein so that could be used against hepatitis C virus and is currently under Phase II trail.
Anguizole is a small molecule inhibitor of HCV replication and alters NS4B's subcellular distribution.
Ombitasvir, a NS5A inhibitor, could be effective in the treatment of HCV as an antiviral agent. IC50: 14 pM and 5 pM (EC50) for genotype 1a-H77 and 1b-Con1 resp...
RO-9187 is a potent inhibitor of HCV virus replication in the replicon system. It is excellent substrates for deoxycytidine kinase and were phosphorylated with ...
Daclatasvir, inhibits the HCV protein NS5A, and thus can be used as a drug candidate for the treatment of hepatitis C (HCV).